Nabriva Therapeutics Announces First Patient Enrolled in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

DUBLIN, Ireland and FORT WASHINGTON, Pa., April 11, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV),...

Related Keywords

United States ,Ireland ,Dublin ,Kim Anderson ,Christine Guico Pabia ,Cf Foundation Patient Registry ,Drug Administration ,Merck Co ,Nasdaq ,Exchange Commission ,Nabriva Therapeutics Us Inc ,Cystic Fibrosis Foundation Patient Registry ,Chief Medical ,Patient Registry Report ,Nabriva Therapeutics ,Important Safety Information ,Full Prescribing Information ,Nabriva Therapeutic ,Private Securities Litigation Reform Act ,Fibrosis Foundation Patient Registry ,Annual Data Report ,新浪香港 ,新浪 ,新浪網 ,香港 ,Sina ,Sina Com Hk ,Hong Kong ,